Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35:20 2023-02-07 am EST
10586.00 GBX   +0.06%
12:01pForxiga approved in EU for chronic heart failure
AQ
10:56aUK earnings, trading statements calendar - next 7 days
AN
08:18aWorld Press Review: February 7
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say

12/09/2022 | 07:00am EST

(Changes percentage to 26% from 20% in 9th paragraph and tumor protein to low HER2 versus no-HER2 from ER)

Dec 9 (Reuters) - The rush to use AstraZeneca and Daiichi-Sankyo's drug Enhertu to treat certain types of breast cancer has far outpaced doctors' ability to determine with certainty which patients might benefit, experts said this week at a meeting of breast cancer doctors.

Enhertu, which won U.S. approval in late 2019, is used in patients with advanced breast, gastric and lung cancers whose tumor cells carry a protein called HER2.

Early this year, researchers found that Enhertu could also benefit certain breast cancer patients whose HER2 levels were previously thought to be too low for the drug to have a meaningful effect.

In August, the U.S. Food and Drug Administration approved Enhertu for treating HER2-low breast cancers that were inoperable or had spread to the brain or elsewhere in the body.

About 50% to 60% of breast cancer patients likely fall into the low-HER2 category, according to the National Cancer Institute. These patients formerly had limited treatment options, but Enhertu's approval for metastatic breast cancer has been changing the way doctors treat them.

The tests which most pathologists now use to look for HER2 in patients' tumors, however, were designed to measure large amounts of the protein and are imprecise in patients with low HER2, several researchers noted in presentations on Wednesday at the San Antonio Breast Cancer Symposium.

Using these so-called immunohistochemistry tests to quantify low levels of HER2 "is like weighing mice on a scale built for elephants," Dr. David Rimm of Yale University said at the meeting.

Pathologists interpret the results subjectively, and "about 50% to 60% get it right," he said.

A report in JAMA Oncology in April showed only a 26% agreement rate among 18 pathologists asked to interpret immunohistochemistry tests for low HER2 versus no HER2.

Enhertu delivers a combination of the monoclonal antibody trastuzumab and the chemotherapy drug deruxtecan.

Roughly 10% of patients taking Enhertu develop a life-threatening lung disease from it, making accurate patient selection particularly important, Rimm noted.

Colorado-based Theralink Technologies Inc has a commercially available quantitative HER2 assay that appears to provide a more accurate assessment.

Theralink reported at the meeting that when it used its quantitative assay to look for HER2 in 175 patients with negative immunohistochemistry tests, 30% to 40% had "modest to moderate" HER2 levels.

Rimm's lab at Yale also has developed a quantitative assay which it has not yet commercialized.

AstraZeneca did not responded to a request for comment.

Given how subjective current tests are, oncologists will often ask pathologists to take a second look at a patient's negative HER2 test, hoping for a different answer, Rimm said in an interview.

"Doctors faced with radiating a patient's brain would much rather be able to give that patient a drug," he said. "If we really want precision medicine and not persuasive medicine, doctors need to demand that pathologists use quantitative analytic assays." (Reporting by Nancy Lapid; editing by Caroline Humer and Bill Berkrot)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.06% 10586 Delayed Quote.-5.69%
DAIICHI SANKYO CO., LTD. -0.42% 4070 Delayed Quote.-3.84%
THERALINK TECHNOLOGIES, INC. 12.00% 0.0028 Delayed Quote.-26.47%
All news about ASTRAZENECA PLC
12:01pForxiga approved in EU for chronic heart failure
AQ
10:56aUK earnings, trading statements calendar - next 7 days
AN
08:18aWorld Press Review: February 7
MS
06:01aAstraZeneca's Forxiga Approved in Europe for Symptomatic Chronic Heart Failure
MT
05:04aASTRAZENECA : Buy rating from Deutsche Bank
MD
03:24aCORRECT: EU approves AstraZeneca's Forxiga for chronic heart failure
AN
03:06aEU approves AstraZeneca's Forxiga for chronic heart failure
AN
02:36aAstraZeneca Says Forxiga Approved in EU for Heart Failure
DJ
02:29aAstraZeneca's Heart Failure Drug Wins EU Nod for Expanded Use in Full Ejection Fraction..
MT
02/06Drug companies face huge drop in sales in 2023
RE
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 472 M - -
Net income 2022 4 262 M - -
Net Debt 2022 24 206 M - -
P/E ratio 2022 47,1x
Yield 2022 2,32%
Capitalization 197 B 197 B -
EV / Sales 2022 4,98x
EV / Sales 2023 4,70x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 127,17 $
Average target price 155,44 $
Spread / Average Target 22,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC-5.69%197 087
JOHNSON & JOHNSON-6.82%427 102
ELI LILLY AND COMPANY-7.31%320 837
NOVO NORDISK A/S2.13%311 923
ROCHE HOLDING AG-2.27%269 272
MERCK & CO., INC.-6.24%263 757